Market research
GV.PA Genomic Vision Société Anonyme
PA EUR Healthcare
Latest close
As of 29 Dec 2024
Test a moving-average rule with historical data.
Market facts
- Market cap
- 693K
- P/E ratio
- Not available
- Analyst target
- 0.2
- Dividend yield
- Not available
- Beta
- -0.67
Profile
Instrument facts
- Exchange
- PA
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- ISIN
- FR0011799907
- Market cap
- 693K
- P/E ratio
- Not available
- Analyst target
- 0.2
- Dividend yield
- Not available
- Beta
- -0.67
About
About Genomic Vision Société Anonyme
Genomic Vision Société Anonyme, a molecular diagnostics and technology company, engages in the development of single DNA detection tools for research and in vitro diagnostics in France. The company provides FiberPrep, a DNA extraction kit that delivers purified DNA solutions for molecular combing; FiberComb, a molecular combing system, which stretches single DNA molecules onto a vinyl silane glass surface; FiberVision S, an automated scanner that develops life science research applications of single DNA molecules analysis and delivers fluorescence imaging; FiberSmart, an analysis software for replication combing assays; and accessories, which include combicoverslips, disposable DNA reservoirs, coverslips stickers, and bench holders. It offers FiberProbes; HexaCard, a genomic vision molecular combing technology offering a streamline one-stop-shop solution for biomanufacturing industries; TeloSizer, a novel tool for measurements of physical telomere length that can be applied to various model organisms; and EasyComb, EasyScan, and EasyComb Plus services. Genomic Vision Société Anonyme was founded in 2004 and is headquartered in Bagneux, France.
Research context
Genomic Vision Société Anonyme appears in PyInvesting’s Paris Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Diagnostics & Research
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the GV.PA discussion.
5 years, 6 months ago
Genomic Vision Société Anonyme is currently in a long term downtrend where the price is trading 38.4% below its 200 day moving average.
From a valuation standpoint, the stock is 94.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 13.9.
Based on the above factors, Genomic Vision Société Anonyme gets an overall score of 1/5.